$IVDA
Iveda Solutions, Inc. Stock $ivda

$ivda Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224012417 Filed on April 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$346.8K	$1.026M	$6.496M
YoY Change	-84.27%	-51.57%	45.38%
Cost Of Revenue	$164.9K	$868.1K	$5.428M
YoY Change	-90.41%	-52.8%	54.88%
Gross Profit	$181.9K	$158.1K	$1.068M
YoY Change	-62.63%	-43.47%	10.81%
Gross Profit Margin	52.45%	15.4%	16.44%
Selling, General & Admin	$1.343M	$1.291M	$4.479M
YoY Change	29.42%	5.66%	4.33%
% of Gross Profit	738.32%	816.66%	419.49%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$7.900K	-$250.00	$19.75K
YoY Change	57.06%	-105.36%	10.95%
% of Gross Profit	4.34%	-0.16%	1.85%
Operating Expenses	$1.343M	$1.291M	$4.479M
YoY Change	29.42%	5.66%	4.33%
Operating Profit	-$1.161M	-$1.133M	-$3.411M
YoY Change	110.72%	20.23%	2.45%
Interest Expense	$4.285K	$26.09K	$124.6K
YoY Change	728.82%	104.79%	133.73%
% of Operating Profit
Other Income/Expense, Net	$73.63K	-$6.060K	-$28.10K
YoY Change	279.56%	-65.37%	116.09%
Pretax Income	-$1.087M	-$1.113M	-$3.314M
YoY Change	104.56%	17.52%	-0.83%
Income Tax	$31.34K	-$80.00	$18.31K
% Of Pretax Income
Net Earnings	-$1.108M	-$1.099M	-$3.235M
YoY Change	101.39%	16.02%	-3.29%
Net Earnings / Revenue	-319.58%	-107.07%	-49.8%
Basic Earnings Per Share	-$0.07		-$0.20
Diluted Earnings Per Share	-$0.07	-$0.07	-$0.20
COMMON SHARES
Basic Shares Outstanding	16.17M shares	16.07M shares	15.97M shares
Diluted Shares Outstanding	16.17M shares		15.97M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.899M	$4.755M	$4.755M
YoY Change	-53.47%	-34.98%	-34.98%
Cash & Equivalents	$3.899M	$4.755M	$4.755M
Short-Term Investments
Other Short-Term Assets	$558.4K	$565.4K	$565.4K
YoY Change	243.69%	51.98%	12.73%
Inventory	$490.4K	$324.5K	$324.5K
Prepaid Expenses		$236.1K
Receivables	$203.9K	$281.1K	$281.1K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$5.279M	$5.926M	$5.926M
YoY Change	-44.82%	-38.04%	-38.04%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.071M	$891.2K	$891.2K
YoY Change	423.8%	2607.88%	2607.96%
Goodwill
YoY Change
Intangibles		$792.6K
YoY Change
Long-Term Investments
YoY Change
Other Assets	$252.2K	$444.7K	$444.7K
YoY Change	-12.61%	66.32%	66.32%
Total Long-Term Assets	$1.323M	$1.336M	$1.336M
YoY Change	168.39%	344.86%	344.86%
TOTAL ASSETS
Total Short-Term Assets	$5.279M	$5.926M	$5.926M
Total Long-Term Assets	$1.323M	$1.336M	$1.336M
Total Assets	$6.602M	$7.261M	$7.261M
YoY Change	-34.36%	-26.38%	-26.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$269.9K	$180.0K	$180.0K
YoY Change	-43.56%	-50.07%	-50.07%
Accrued Expenses	$783.4K	$900.9K	$900.9K
YoY Change	-0.74%	-27.52%	-27.52%
Deferred Revenue
YoY Change
Short-Term Debt	$250.5K	$348.8K	$348.8K
YoY Change	52.95%	-12.46%	-12.46%
Long-Term Debt Due	$125.2K
YoY Change	91.19%
Total Short-Term Liabilities	$1.477M	$1.459M	$1.459M
YoY Change	-4.24%	-30.61%	-30.61%
LONG-TERM LIABILITIES
Long-Term Debt	$480.0K	$0.00	$0.00
YoY Change	174.84%	-100.0%	-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$480.0K	$0.00	$0.00
YoY Change	174.84%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.477M	$1.459M	$1.459M
Total Long-Term Liabilities	$480.0K	$0.00	$0.00
Total Liabilities	$1.957M	$1.360M	$1.360M
YoY Change	13.97%	-40.71%	-40.71%
SHAREHOLDERS EQUITY
Retained Earnings	-$49.05M	-$47.94M
YoY Change	8.38%	7.24%
Common Stock	$162.00	$162.00
YoY Change	1.89%	8.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.755M	$5.902M	$5.902M
YoY Change
Total Liabilities & Shareholders Equity	$6.602M	$7.261M	$7.261M
YoY Change	-34.36%	-26.38%	-26.38%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.108M	-$1.099M	-$3.235M
YoY Change	101.39%	16.02%	-3.29%
Depreciation, Depletion And Amortization	$7.900K	-$250.00	$19.75K
YoY Change	57.06%	-105.36%	10.95%
Cash From Operating Activities	-$1.112M	-$734.6K	-$2.605M
YoY Change	-744.45%	-65.22%	-51.84%
INVESTING ACTIVITIES
Capital Expenditures	$188.4K	$238.2K	$878.2K
YoY Change	6.95%	2549.72%	6099.86%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$188.4K	-$238.2K	-$878.2K
YoY Change	6.95%	2549.72%	6099.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.323M
YoY Change			-88.51%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$523.3K	84.10K	924.1K
YoY Change	-51.19%	-107.12%	-91.9%
NET CHANGE
Cash From Operating Activities	-$1.112M	-734.6K	-2.605M
Cash From Investing Activities	-$188.4K	-238.2K	-878.2K
Cash From Financing Activities	$523.3K	84.10K	924.1K
Net Change In Cash	-$855.4K	-888.8K	-2.559M
YoY Change	-180.12%	-73.09%	-143.17%
FREE CASH FLOW
Cash From Operating Activities	-$1.112M	-$734.6K	-$2.605M
Capital Expenditures	$188.4K	$238.2K	$878.2K
Free Cash Flow	-$1.300M	-$972.9K	-$3.483M
YoY Change	36094.68%	-54.14%	-35.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2023	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax		usd
CY2022	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax		usd
CY2023	IVDA	Common Stock Warrants Issued For Interest CommonStockWarrantsIssuedForInterest		usd
CY2022	IVDA	Common Stock Warrants Issued For Interest CommonStockWarrantsIssuedForInterest		usd
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt		usd
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent		usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt		usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards		usd
CY2022Q4	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Public Float EntityPublicFloat	9500000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16169891	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2023	dei	Auditor Firm AuditorFirmId	5041
CY2023	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4754597	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7312095	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	129778	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	129527	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	281049	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1222690	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	324515	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	526470	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	435580	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	371990	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5925520	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	9562772	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	891187	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	32911	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	444723	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	267387	usd
CY2023Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	444723	usd
CY2022Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	267387	usd
CY2023Q4	us-gaap	Assets Assets	7261430	usd
CY2022Q4	us-gaap	Assets Assets	9863070	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1110087	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1638727	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	348771	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	398409	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	65408	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1458858	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2102544	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	190776	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2023Q4	IVDA	Non Controlled Interest In Joint Ventures NonControlledInterestInJointVentures	-99048	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	5802572	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7569750	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6495865	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4468279	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	5428261	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	3504778	usd
CY2023	us-gaap	Gross Profit GrossProfit	1067604	usd
CY2022	us-gaap	Gross Profit GrossProfit	963501	usd
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4478553	usd
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4292820	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	4478553	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4292820	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3329320	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-28099	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	131881	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	57397	usd
CY2023	us-gaap	Interest Expense InterestExpense	7254	usd
CY2022	us-gaap	Interest Expense InterestExpense	53323	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	96527	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13004	usd
CY2023	us-gaap	Noncontrolling Interest In Net Income Loss Joint Venture Partners Nonredeemable NoncontrollingInterestInNetIncomeLossJointVenturePartnersNonredeemable	-97605	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3216817	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3342324	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18308	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2947	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-777279	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Ownshare Lending Arrangement Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts	-1163918	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	120581	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	219900	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	5555	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	23000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8011250	usd
CY2022	IVDA	Common Stock And Prefunded Warrant Offering CommonStockAndPrefundedWarrantOffering	4999836	usd
CY2022	IVDA	Adjustments To Additional Paid In Capital Warrants Sold In Over Allotment AdjustmentsToAdditionalPaidInCapitalWarrantsSoldInOverAllotment	2797	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3345270	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-77150	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7569750	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7569750	usd
CY2023	IVDA	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	1322885	usd
CY2023	IVDA	Stock Issued Value Joint Venture Partners Non Controlled Equity Interest StockIssuedValueJointVenturePartnersNonControlledEquityInterest	99048	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	5802572	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	5802572	usd
CY2022Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-8
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3235124	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3345270	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19753	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17801	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	104600	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	120581	usd
CY2023	IVDA	Common Stock Warrants Issued For Services CommonStockWarrantsIssuedForServices	2700	usd
CY2022	IVDA	Common Stock Warrants Issued For Services CommonStockWarrantsIssuedForServices	5555	usd
CY2023	IVDA	Common Stock Issued For Services CommonStockIssuedForServices	138546	usd
CY2022	IVDA	Common Stock Issued For Services CommonStockIssuedForServices	219900	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-930803	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	785969	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-199124	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	214898	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	66995	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	168122	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	175592	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	19919	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-522460	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-1238379	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2604645	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5408720	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	878205	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14165	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-878205	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14165	usd
CY2023	IVDA	Proceeds From Repayments Of Changes In Restricted Cash ProceedsFromRepaymentsOfChangesInRestrictedCash	-685	usd
CY2022	IVDA	Proceeds From Repayments Of Changes In Restricted Cash ProceedsFromRepaymentsOfChangesInRestrictedCash	-214	usd
CY2023	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-47554	usd
CY2022	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	358888	usd
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-300000	usd
CY2023	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-251498	usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-164093	usd
CY2023	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-99048	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1322885	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11511741	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	924100	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11406322	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1252	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-56617	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2557499	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5926820	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7312095	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1385275	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4754596	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	7312095	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	9793	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	53323	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	28779	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_z6JeXWjVJqq5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_862_zLrBWMuVsyf9">Use of Estimates</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_z419dsc3nVVb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_867_zo6LjJ42foo7">Concentrations</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash and cash equivalents and trade accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially all cash is deposited in three financial institutions, two in the United States and one in Taiwan. At times, amounts on deposit in the United States may be in excess of the FDIC insurance limit. Deposits in Taiwan financial institutions are insured by CDIC (Central </span>Deposit Insurance Corporation) with maximum coverage of NTD <span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pn6n6_uNTD_c20231231_zaMFHgg7Yki6">3 </span>million. At times, amounts on deposit in Taiwan may be in excess of the CDIC Insurance limit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivables are unsecured, and we are at risk to the extent such amount becomes uncollectible. We perform periodic credit evaluations of our customers’ financial condition and generally do not require collateral. <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ChunghwaTelecomMember_zn2ZrtWL9zld" title="Concentration risk, percentage">50</span>% of the total accounts receivable at December 31, 2023 was from one customer out of a total of 24 customer accounts receivable accounts. This specific customer was Chunghwa Telecom. At December 31, 2022 one customer out of a total of 36 customer accounts receivable accounts was <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ChunghwaTelecomMember_zf4tVNS29Ei4" title="Concentration risk, percentage">52</span>% of the total accounts receivable. This specific customer was Chicony Power Technology Co Ltd. These customers are longtime customers, and we don’t expect any problem with collectability of these accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue from two customers out of 65 total customers represented approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TaiwanCoMember_zOcSYNL7Tmol" title="Concentration risk, percentage">48</span>% of total revenue for the year ended December 31, 2023. These specific customers were 1) YOU MING HUEI CO. LTD with <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__dei--LegalEntityAxis__custom--YouMingHueiCoLtdMember_z4UL8TSfOzLg" title="Concentration risk, percentage">25</span>%, 2) Chicony Power Technology Co Ltd with <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__dei--LegalEntityAxis__custom--ChiconyPowerTechnologyMember_z5KGjSFdBu53" title="Concentration risk, percentage">23</span>%, (both Taiwan companies).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue from two customers out of 42 total customers represented approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TaiwanCoMember_zAanQJuQVfdj" title="Concentration risk, percentage">52</span>% of total revenue for the year ended December 31, 2022. These specific customers were 1) Chunghwa Telecom with <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__dei--LegalEntityAxis__custom--ChunghwaTelecomMember_z8szwlSPGsgg" title="Concentration risk, percentage">21</span>%, 2) Chicony Power Technology Co Ltd with <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__dei--LegalEntityAxis__custom--ChiconyPowerTechnologyMember_zZtv5PhpuD7l" title="Concentration risk, percentage">31</span>%, (both Taiwan companies).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No other customers represented greater than <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_zCjI8isz6rmj" title="Percentage of concentration risk"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OtherCustomersMember__srt--RangeAxis__srt--MinimumMember_zrtgeh3hHIU1" title="Percentage of concentration risk">10</span></span>% of total revenues in years ended December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	3000000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	usd
CY2022	us-gaap	Depreciation Depreciation	17801	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	179949	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	360395	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	900928	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1243027	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	29211	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	35305	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1110087	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1638727	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	104600	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	120581	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_848_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zfv6TTF2KRDh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_863_z03scp2cDnN5">Reclassification</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts in 2022 have been reclassified to conform to the 2023 presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	348771	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	398409	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	65408	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	190776	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	93887	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1014438	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.61
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	893438	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.80
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	233125	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.68
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	233125	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.26
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	10938	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.35
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	112125	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	16.19
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1301000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.50
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1014438	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.61
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1260375	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.62
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	959750	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.61
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.34
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.92
CY2023	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	0.32
CY2023	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	17.76
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1301000	shares
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y6M
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	4.50
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	1260375	shares
CY2023Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	4.62
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.90	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.90	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0400	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0100	pure
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	6233660	shares
CY2022Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	2.66
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	872259	shares
CY2021Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	3.04
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	11250	shares
CY2023	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice	0.72
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	5616224	shares
CY2022	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsGrantedWeightedAverageExercisePrice	2.96
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	945900	shares
CY2023	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice	1.40
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	8214	shares
CY2022	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisedWeightedAverageExercisePrice	2.80
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	245114	shares
CY2023	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeited Cancelled Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeitedCancelledWeightedAverageExercisePrice	3.34
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	246609	shares
CY2022	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeited Cancelled Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeitedCancelledWeightedAverageExercisePrice	2.80
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	5053896	shares
CY2023Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	2.84
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	6233660	shares
CY2022Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	2.66
CY2023Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	5053896	shares
CY2023Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice	2.84
CY2022Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	6233660	shares
CY2022Q4	IVDA	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableWeightedAverageExercisePrice	2.66
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.24
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	14800000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	11800000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	14800000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11800000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3000000	usd
CY2023	IVDA	Year Of Expiration YearOfExpiration	2043
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3000000	usd
CY2022	IVDA	Year Of Expiration YearOfExpiration	2042
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1000000	usd
CY2021	IVDA	Year Of Expiration YearOfExpiration	2041
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	590000	usd
CY2020	IVDA	Year Of Expiration YearOfExpiration	2040
CY2019Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	260000	usd
CY2019	IVDA	Year Of Expiration YearOfExpiration	2039
CY2018Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	160000	usd
CY2018	IVDA	Year Of Expiration YearOfExpiration	2038
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	140000	usd
CY2017	IVDA	Year Of Expiration YearOfExpiration	2037
CY2016Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1640000	usd
CY2016	IVDA	Year Of Expiration YearOfExpiration	2036
CY2015Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	3400000	usd
CY2015	IVDA	Year Of Expiration YearOfExpiration	2035
CY2014Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5230000	usd
CY2014	IVDA	Year Of Expiration YearOfExpiration	2034
CY2013Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	5600000	usd
CY2013	IVDA	Year Of Expiration YearOfExpiration	2033
CY2012Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2850000	usd
CY2012	IVDA	Year Of Expiration YearOfExpiration	2032
CY2011Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	2427000	usd
CY2011	IVDA	Year Of Expiration YearOfExpiration	2031
CY2010Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1799000	usd
CY2010	IVDA	Year Of Expiration YearOfExpiration	2030
CY2009Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1750000	usd
CY2009	IVDA	Year Of Expiration YearOfExpiration	2029
CY2008Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1308000	usd
CY2008	IVDA	Year Of Expiration YearOfExpiration	2028
CY2007Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	429000	usd
CY2007	IVDA	Year Of Expiration YearOfExpiration	2027
CY2006Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	476000	usd
CY2006	IVDA	Year Of Expiration YearOfExpiration	2026
CY2005Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	414000	usd
CY2005	IVDA	Year Of Expiration YearOfExpiration	2025
CY2023	IVDA	Taiwan Corporate Tax Rate TaiwanCorporateTaxRate	Sole-Vision Technologies, Inc. is a subsidiary of the Company which is operating in Taiwan as a profit-seeking enterprise. Its applicable corporate income tax rate is 17%. In addition, Taiwan’s corporate tax system allows the government to levy a 10% profit retention tax on undistributed earnings for the prior year. This tax will not be provided if the company distributed the earnings before the ended of the fiscal year
CY2023	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	90000	usd
CY2022	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	90000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-3235124	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3345270	usd
CY2023	IVDA	Weighted Average Shares Outstanding Basic WeightedAverageSharesOutstandingBasic	15973422	shares
CY2022	IVDA	Weighted Average Shares Outstanding Basic WeightedAverageSharesOutstandingBasic	12840598	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26

Files In Submission

Name	View Source	Status
0001493152-24-012417-index-headers.html	Edgar Link	pending
0001493152-24-012417-index.html	Edgar Link	pending
0001493152-24-012417.txt	Edgar Link	pending
0001493152-24-012417-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k001.jpg	Edgar Link	pending
ivda-20231231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ivda-20231231_cal.xml	Edgar Link	unprocessable
ivda-20231231_def.xml	Edgar Link	unprocessable
ivda-20231231_lab.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ivda-20231231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IVDA
Iveda Solutions, Inc. Stock $ivda

2024 Q1 Form 10-K Financial Statement

#000149315224012417 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IVDA Iveda Solutions, Inc. Stock $ivda

2024 Q1 Form 10-K Financial Statement

#000149315224012417 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IVDA
Iveda Solutions, Inc. Stock $ivda